Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment

Hirano, Kenji; Tada, Minoru; Isayama, Hiroyuki; Yagioka, Hiroshi; Sasaki, Takashi; Kogure, Hirofumi; Nakai, Yousuke; Sasahira, Naoki; Tsujino, Takeshi; Yoshida, Haruhiko; Kawabe, Takao; Omata, Masao
December 2007
Gut;Dec2007, Vol. 56 Issue 12, p1719
Academic Journal
Objectives: Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis, and has a favourable response to corticosteroid treatment (CST). Little is known, however, about the long-term outcome of AlP. This study aimed to document the prognosis without and with CST, and to examine the indication for CST. Patients and methods: The prognosis and clinical features of 23 patients without CST and 19 patients treated with CST from onset were investigated. In addition, factors concerning the late occurrence of unfavourable events related to AlP were examined. Results: The patients without CST were 19 men and four women, with an average age of 66 years. After an average observation period of 25 months, 16 patients (70%) developed unfavourable events including obstructive jaundice as a result of distal bile duct stenosis in four, growing pseudocyst in one, sclerogenic changes of extrapancreatic bile duct in nine, hydronephrosis as a result of retroperitoneal fibrosis in one, and interstitial nephritis in one. Patients with obstructive jaundice at onset showed a higher cumulative event occurrence rate (p=0.025). The patients treated with CST were 16 men and three women, with an average age of 64 years. After an average observation period of 23 months, six patients (32%) developed unfavourable events consisting of interstitial pneumonia in three, and a recurrence of obstructive jaundice in three. In multivariate analysis, CST (HR 0.33, 95% Cl 0.12-0.89, p = 0.029) and obstructive jaundice at onset (HR 3.09, 95% Cl 1.14-8.32, p = 0.026) were significant predictive factors for unfavourable events. Conclusion: CST could reduce AlP-related unfavourable events. The early introduction of CST is recommended especially for patients with obstructive jaundice.


Related Articles

  • Inhaled corticosteroids and risk of cataract formation. Kirchner, Jeffrey T. // American Family Physician;12/1/1997, Vol. 56 Issue 9, p2333 

    Presents the summary of the article `Use of Inhaled Corticosteroids and the Risk of Cataracts,' by R.G. Cumming from the `Northern England Journal of Medicine' dated 1997. Effects of inhaled corticosteroids; Cumulative lifetime dosage of beclomethasone.

  • Autoimmune pancreatitis in Japan: overview and perspective. Shimosegawa, Tooru; Kanno, Atsushi // Journal of Gastroenterology;2009, Vol. 44 Issue 6, p503 

    Since the rediscovery and definition of autoimmune pancreatitis (AIP) by Yoshida et al. in 1995, the disease has been attracting attention because of its unique clinical features and practical issues. This disease shows very impressive imaging findings, serological changes, and characteristic...

  • a closer look at corticosteroids. DUNKIN, MARY ANNE // Arthritis Today;Jul/Aug2012, Vol. 26 Issue 4, p54 

    The article discusses corticosteroids, which are used to treat inflammatory forms of arthritis, including rheumatoid arthritis, lupus and ankylosing spondylitis. The various forms and uses of corticosteroids are listed, including oral, intravenous and ocular. Solutions to common side effects of...

  • Corticosteroid Therapy for Chronic Active Hepatitis. Berk, Paul D.; Jones, E. Anthony // Annals of Internal Medicine;Oct76, Vol. 85 Issue 4, p523 

    Editorial. Offers observation on published reports of studies on the use of corticosteroid for the treatment of chronic active hepatitis. Brief background on the term chronic active hepatitis; Views on the therapy; Effect of remission.

  • Low-dose oral steroids yielded similar outcomes as higher-dose IV steroids in patients with COPD.  // Infectious Disease News;Aug2010, Vol. 23 Issue 8, p21 

    The article discusses research being done on the effectiveness of oral corticosteroid therapy as intravenous corticosteroid therapy in treating patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease, which references the study by P. K. Lindenauer in the journal...

  • American Thoracic Society Intl Conference Long-term ICS use reduces pleural effusion in patients with CAP.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article focuses on a study according to which prior treatment with inhaled corticosteroids in patients with respiratory disorders who develop community acquired pneumonia (CAP) is associated with a lower incidence and severity of parapneumonic effusion.

  • Corticosteroid use and MetS in systemic lupus erythematosis.  // Reactions Weekly;9/15/2012, Issue 1419, p2 

    The article reports on a study which found that corticosteroid and immunosuppressant use are among the risk factors for the metabolic syndrome (MetS) in systemic lupus erythematosus (SLE) patients.

  • Are glucocorticoids really useful for the treatment of acute pancreatitis? Shimosegawa, Tooru // Journal of Gastroenterology;2002, Vol. 37 Issue 7, p580 

    Editorial. Comments on the issue regarding the effectiveness of glucocorticoids for the treatment of acute pancreatitis. Benefit of corticosteroids in human pancreatitis; Role of corticosteroids in the treatment of acute pancreatitis; Details of the important event related to the pathogenesis...

  • Pemphigus vulgaris during pregnancy -- a case report. Ali, Habiba Sharaf // Journal of Pakistan Association of Dermatologists;Oct-Dec2011, Vol. 21 Issue 4, p301 

    Pemphigus vulgaris (PV) is an uncommon immune-mediated bullous dermatosis which is very rare during pregnancy. Its management during pregnancy is a challenge and sometimes very difficult. Only few cases have been reported in literature so far. The disease may be associated with adverse fetal...


Read the Article


Sign out of this library

Other Topics